Onkologie. 2026:20(3):163-168 | DOI: 10.36290/xon.2026.030
Multidisciplinary collaboration in radioligand therapy of prostate cancer
- 1 Urologická klinika, 1. LF UK a VFN, Praha
- 2 Onkologická klinika, 1. LF UK a VFN, Praha
- 3 Radiodiagnostická klinika, 1. LF UK a VFN, Praha
- 4 Ústav nukleární medicíny, 1. LF UK a VFN, Praha
Radioligand therapy (RLT) targeting the prostate-specific membrane antigen (PSMA) represents a significant advance in the treatment of metastatic castration-resistant prostate cancer. The implementation of this modality into clinical practice places high demands on appropriate patient selection, organizational support, and the safe delivery of treatment. This article summarizes the role of the multidisciplinary team (MDT) in PSMA-targeted RLT for prostate cancer and outlines the key responsibilities of individual specialists, including the clinical oncologist, urologist, nuclear medicine physician, radiologist, and specialized nurse. Particular attention is paid to care coordination, MDT communication, and the practical aspects of the treatment day. Based on clinical experience at the General University Hospital in Prague, a functional MDT model is presented that enables the safe, effective, and seamless integration of RLT into comprehensive oncological care.
Keywords: radioligand therapy, prostate cancer, multidisciplinary team.
Accepted: June 15, 2026; Published: July 1, 2026 Show citation
References
- Pluvicto (lutecium-[177lu] vipivotid tetraxetan): Souhrn údajů o přípravku. Available from: https://www.ema.europa.eu/cs/documents/product-information/pluvicto-epar-product-information_cs.pdf. [cited 21. 2. 2026 ]
- Williams GJ, Thompson JF. Management changes and survival outcomes for cancer patients after multidisciplinary team discussion; a systematic review and meta-analysis. Cancer Treat Rev. 2025;139:102997.
Go to original source... - Zhu S, Chen J, Ni Y, et al. Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients. Prostate. 2021;81(11):721-727. Go to original source...
- Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091-1103. Go to original source...
- Calais J, Eulau SM, Gardner L, et al. Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer. Cancer Treat Rev. 2023;115:102524. Go to original source...
- Murphy DG, Hofman MS, Azad A, et al. Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team. BJU Int. 2019;124(4):551-553. Go to original source...
- Calais J, Czernin J. PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy. J Nucl Med. 2021;62(11):1489-1491. Go to original source...
- Kopp RP, Marshall LM, Wang PY, et al. The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors. Eur Urol. 2013;64(4):672-679. Go to original source...
- Mench A, Winters C, Mittra E, et al. Navigating Radiation Safety After Radiopharmaceutical Therapies: Proposed Workflow and Essential Guidelines for Nonspecialists. J Nucl Med. 2025;66(7):990-994. Go to original source...
- European Society of Radiology (ESR). "Role of radiology in a multidisciplinary approach to patient care": summary of the ESR International Forum 2022. Insights Imaging. 2023;14(1):26. Go to original source...
- Spitz A, Floyd R, Sutton J, et al. Practical Guidance on [177Lu]Lu-PSMA-617 Treatment, Including Radiation Safety, Adverse Event Monitoring, and Patient Counseling. Clin J Oncol Nurs. 2023;27(5):539-547.
- Boothe DL, De La Cerda J, Graves SA, et al. Administering radioligand therapy: day of delivery workflow and radiation safety precautions [poster]. Network for Collaborative Oncology Development & Advancement (NCODA); 2025. Available from: https://www.ncoda.org/wp-content/uploads/2025/10/25-09-05_Day-of-Delivery_NCODA-PST_FIN.pdf. [cited 21. 2. 2026].